Skip to Content

Dalbavancin Pregnancy and Breastfeeding Warnings

Dalbavancin is also known as: Dalvance

Medically reviewed on July 23, 2018

Dalbavancin Pregnancy Warnings

No evidence of embryo or fetal toxicity was found in animal studies at 0.7 and 1.2 times the human dose; at 3.5 times the human dose, delayed fetal maturation, increased embryo lethality, and increased offspring deaths during the first week post-partum were seen. There are no adequate or well-controlled studies in pregnant women.

US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

This drug should be used during pregnancy only if the benefit outweighs the risk.

US FDA pregnancy category: C

See references

Dalbavancin Breastfeeding Warnings

Caution is recommended.

Excreted into human milk: Unknown
Excreted into animal milk: Yes

See references

References for pregnancy information

  1. "Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc., Chicago, IL.

References for breastfeeding information

  1. "Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc., Chicago, IL.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide